WJ-01075

Dose escalation phase (Phase Ia) Primary objectives: To evaluate the safety and tolerability of WJ01075 tablets in patients with advanced malignant solid tumors; To evaluate the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of WJ01075 tablets in patients with advanced malignant solid tumors, and to preliminarily explore the Phase II dosing dose (RP2D); Secondary objectives: To evaluate the pharmacokinetic (PK) characteristics of WJ01075 tablets in patients with advanced solid tumors; Preliminary evaluation of the efficacy of WJ01075 tablets in patients with advanced solid tumors. Extension phase (Phase Ib) The Phase Ib study plans to conduct a multi-tumor cohort expansion study to further evaluate the PK characteristics, safety and preliminary efficacy of WJ01075 tablets in patients with advanced malignant solid tumors. Exploratory objectives (applicable to all phases) To explore the relationship between the exposure/dose of WJ01075 tablets and safety and clinical efficacy; To explore the possible metabolic pathways of WJ01075 tablets: to identify the main metabolites in plasma.